Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Synonyms
Fluvoxamine
Fluvoxamina
Fluvoxamine maleate
Fluvoxaminum
Brand Names
Novo-fluvoxamine
Ava-fluvoxamine
PHL-fluvoxamine
Riva-fluvox
Riva-fluvox 50mg Tablets
Fluvoxamine Tablets
Fluvoxamine-100
Dom-fluvoxamine
Sandoz Fluvoxamine
Gen-fluvoxamine 100mg
Luvox CR
Apo-fluvoxamine
Fluvoxamine Maleate
Fluvoxamine maleate
Riva-fluvox 100mg Tablets
Ratio-fluvoxamine
Gen-fluvoxamine 50mg
Fluvoxamine-50
Fluvoxamine
Bci Fluvoxamine Tablets
Luvox
Teva-fluvoxamine
PMS-fluvoxamine
Indication
Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [A250].
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
